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Abstract 
BACKGROUND: Health related quality of life is an important outcome measure in studies involving patients with chronic 
neurological conditions. Disease specific patient reported outcome measures (PROMs) are increasingly used as primary 
end points in clinical trials. The most widely used disease specific PROM is the 39 item Parkinson's Disease Question-
naire (PDQ-39). The aim of this study was to determine validity and reliability of Persian PDQ-39. 
METHODS: Two hundred Parkinson's disease patients attending neurologic clinics of teaching hospitals were recruited. 
PD patients completed a translated version of the PDQ-39. Internal consistency reliability of the questionnaire was as-
sessed by Cronbach's alpha coefficient. Reproducibility was assessed across the 3-week interval using the intraclass 
correlation coefficient. To assess convergent validity, results on the PDQ-39 were correlated with those gained on the 
SF-36. Discriminate validity of questionnaire was assessed by comparing PDQ-39 scores and the severity and the dura-
tion of disease. 
RESULTS: A value of 0.93 (Cronbach's α) was gained for the summary score (PDQ-SI), indicating high levels of internal 
reliability. Alpha value of seven domains was greater than 0.70. The intraclass correlation coefficient ranged from 0.47 
to 0.90. The range of correlation coefficients between domains of SF-36 and PDQ-SI was from -0.40 to -0.61. There 
was a statistically significant difference between severity of disease and mean scores of PDSI. 
CONCLUSIONS: This study provides evidence that the Persian version of PDQ-39 is a valid and reliable measure of qual-
ity of life in PD. 
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arkinson's disease (PD) is a chronic neu-
rodegenerative disease. It is more com-
mon in males than females, and preva-
lence increases markedly with age, being ex-
tremely rare in those under the age of 45 years 
and being present in about 1% of those over 65 
years, and 2% over 85.1 There is a marked ap-
parent geographical variation, with low preva-
lence rates in China and Africa. This disease 
impacts many areas including mobility, cogni-
tions, social function, psychological status, 
speech, communication and economic/ 
occupational functioning.2-5 
The main focus in evaluation and treatment 
of patients with Parkinson's disease has been 
on the motor disability of the disease. How-
ever, non-motor symptoms like mood changes, 
cognitive impairment and sleep disturbances 
often complicate the course of the disease and 
impact on the patient's life.6-8 The aim of treat-
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ment and medical interventions is largely fo-
cused at decreasing the impact of this disease 
on the quality of life of affected patients. 
Health related quality of life (HRQoL) is con-
sidered to be an important outcome measure in 
studies involving patients with chronic dis-
eases. In recent years emphasis has been 
placed on measuring the subjective experience 
of patients, incorporating the effect of the dis-
ease and its treatment from the patient's point 
of view.5
The Parkinson's disease Questionnaire 
(PDQ-39) is the most commonly used HRQoL-
specific PD measure. This instrument was 
originally developed in the United Kingdom.9
The PDQ-39 was designed to be a valid and 
feasible questionnaire for self-completion that 
addresses the perceptions and concerns of in-
dividuals with Parkinson's disease. Its primary 
use is intended to be in clinical trials and re-
lated forms of evaluation of interventions. This 
instrument has 39 items covering eight do-
mains of quality of life. To date, the PDQ-39 
has been adapted into more than 60 different 
cultures and languages.10 
With the expected increase in life expec-
tancy in developing countries, included Iran, 
in the next decades, the number and propor-
tion of the elderly will also increase. Therefore, 
it is expected that the prevalence of chronic 
diseases, such as Parkinson's disease will in-
crease too. In order to evaluate the effective-
ness of therapeutic intervention, valid and reli-
able patient reported outcome measures will 
be required.9
The aim of this study was to validate PDQ-
39 questionnaire in Persian language by evalu-
ating internal consistency, test/retest reliabil-
ity, construct validity and discriminate valid-
ity, in a specific group of patients with a diag-




The study was conducted in outpatient clinics 
of the Iran University of Medical Sciences lo-
cated in Tehran. The study was conducted be-
tween June 2008 and April 2009. At each cen-
ter, the PDQ-39 questionnaire was adminis-
tered to consecutive patients attending neuro-
logical hospital clinics with a diagnosis of 
Parkinson's disease confirmed by a specialist 
neurologist. Informed consent was obtained 
from patients after aims of the study were ex-
plained to them. Patients self completed ques-
tionnaires at waiting rooms under the observa-
tion of a trained interviewer. Two hundred 
and forty patients were recruited into the 
study, and two hundred completed question-
naires (83%) were collected. Three weeks later 
the questionnaire was offered to a randomly 
selected sub sample of 15% of the original sub-
jects in order to assess reproducibility. All of 
these subjects returned the questionnaires. The 
inclusion criteria were being less than 90 years 
old and having a confirmed diagnosis of Park-
inson's disease. Exclusion criteria included be-
ing illiterate, showing evidence of another ma-
jor medical illness, showing cognitive impair-
ment or any severe mentally or physically ill-
ness and having dementia. Approval for the 
study was granted by the institutional review 




Two questionnaires were used. Quality of life 
of patients with Parkinson's disease was as-
sessed using the PDQ-39 questionnaire.11 The 
PDQ-39 contains eight domains: mobility (10 
items), activities of daily living (6 items), emo-
tional well-being (6 items), stigma (4 items), 
social support (3 items), cognitions (4 items), 
communication (3 items), and bodily discom-
fort (3 items). Previous research has suggested 
the questionnaire has good internal and test-
retest reliability, as well as a good construct 
and face validity across a wide variety of lan-
guages and cultures.9,12 In this questionnaire 
each item scored from zero to four as the best 
to worst. Each domain score ranges from zero 
(the best QoL) to 100 (the worst QoL). 
 The second questionnaire was the Short-
Form 36 (SF-36) health status survey, which 
has previously been validated in Persian.13 The 
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SF-36 contains eight subscales measuring as-
pects of physical and mental health. Each di-
mension is reported on a scale of 0 to 100 with 
higher score reflected the better quality of life. 
Other variables included demographic vari-
ables (age, marital status, education, and occu-
pation). Clinical variables, including disease 
duration, family history of disease and severity 
of disease were also collected. Disease severity 
was classified according to Hoehn and Yahr 
classification (HY).14 This classification has 5 
stages. Stages were categorized as follow: 
stages I-II as mild, stage III as moderate, and 
stages IV-V as severe. Disease duration was 
categorized as ≤ 5 years and > 5 years. 
 
Translation 
Written permission was obtained from the 
original developers to proceed with the trans-
lation. The PDQ-39 was translated into Persian 
in parallel by two independent, native Iranian 
health professional translators, fluent in both 
English and Persian. Subsequently, two trans-
lators compared the Persian version and origi-
nal English version of questionnaire. Another 
English speaker, with English as her first for-
eign language, who did not have any knowl-
edge of the original instrument, then back 
translated the questionnaire into English. The 
backward translation was sent to the developer 
of the original questionnaire for comparison 
and his suggestions were incorporated into the 
final Persian version. A consensus meeting 
was held between the translators and investi-
gators, during which the back-translation and 
the original scale were compared and any dif-
ferences discussed and resolved. Pre-testing 
was completed with 20 patients to evaluate the 
comprehension and readability of the PDQ-39 
Persian version. Patients were asked whether 
they encountered any difficulty in understand-
ing each of the items. Patients indicated they 
had no problems with the measure and under-
stood the items. 
 
Statistical Analysis 
Internal consistency and reliability of dimen-
sions of the questionnaire were assessed using 
the Cronbach's alpha coefficient. Alpha values 
equal to or greater than 0.70 were considered 
satisfactory. Item-total correlations over 0.70 
were considered to show acceptable correla-
tion between the items of questionnaire and 
the domain total to which they contribute. Re-
producibility (test/retest reliability) was as-
sessed across a 3-week interval on 30 (15%) pa-
tients using the intraclass correlation coeffi-
cient. The recommended level for group com-
parisons is 0.7.15 Convergent validity was 
evaluated by comparing the PDQ-39 and its 
subscales to related measures on the SF-36. To 
assess convergent validity, Pearson's correla-
tion coefficients were used. Due to inverse 
scoring between the two questionnaires, the 
expectation was for correlation coefficient to be 
negative. Discriminate validity of question-
naire was assessed by comparing PDQ-39 
scores and the severity and the duration of dis-
ease. Differences between groups of severity 
were assessed with analysis of variance 
(ANOVA). Scheffè was used as a post hoc test. 
It was hypothesized that higher scores on 
PDQ-39 would be related to greater severity of 
disease. T-tests were used to compare scores 
between two groups of differing disease dura-
tion. Significance was set at 0.05 for all analy-
ses. 
Results 
Two hundred and forty people with Parkin-
son's disease agreed to participate in the study. 
Two hundred (83%) participants completed 
and returned the questionnaires. Mean age 
was 57.3 (SD = 10.5) years (range: 27-83). The 
mean number of years since diagnosis was 6.5 
(SD = 4.2) years. Mean age at onset of disease 
was 50.6 (SD = 11.0) years. Other demographic 
characteristics of the patients are displayed in 
table 1. One hundred and thirty five (67.5%) of 
the respondents were male. One hundred and 
seventy eight (89%) of patients were married. 
Distribution of patients according to severity 
by HY staging was as follow: 46.5% mild; 40% 
moderate; and 11.5% sever. Fifty six (28%) re-
spondents had graduated from high school, 
but  the  majority  had  ceased education before 
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Table 1. Demographic characteristics of Park-
inson's disease patients (n = 200) 
Variable Number % 
Gender 
 Male          








 Less than high 
 school 



























































then. Sixty four (32%) of the respondents were  
retired. Twenty one patients (10.5%) had a 
positive family history of PD between first de-
gree relatives. 
 Descriptive statistics for the PDQ-39 are re-
ported in table 2. Data completion was satisfac-
tory. Only one dimension had 6% missing data 
(mobility). Missing data for other domains was 
less than 5%. 
 Internal consistency was assessed using 
Cronbach's alpha and a value of 0.93 was 
gained for the summary score, indicating high 
levels of internal reliability. Alpha values for 
each subscale ranged from 0.91 (maximum) for 
mobility to 0.60 for cognitions (minimum). The 
intraclass correlation coefficient (ICC) assess-
ing reproducibility at 3 weeks ranged from 
0.90 for mobility to 0.47 for activities of daily 
living. The ICC for PDQ-SI was 0.80. Item-test 
correlation for all items and domains ranged 
from 0.73 to 0.84 (Table 2). 
 Subscales of the PDQ-39 and related meas-
ures of SF-36 showed a significant correlation 
between mobility and physical functioning of 
SF-36 (-0.61, p < 0.01). Also, there were a sig-
nificant correlation between emotions and 
emotional well being of SF-36 (-0.55, p < 0.01) 
and body pain of PDQ-39 with pain domain of 
SF-36 (-0.60, p < 0.01). 
 
Table 2. Descriptive statistics and reliability of PDQ-39 scales 
 





Mobility 44.5 (23.1) 41.0-47.6 0.91 0.79 0.90 
ADL* 39.1 (22.3) 35.2-42.0 0.88 0.83 0.47 
Emotions 37.2 (21.0) 32.8-39.1 0.86 0.84 0.78 
Stigma 33.9 (25.1) 29.8-37.4 0.87 0.73 0.82 
Social 22.9 (20.4) 20.0-26.0 0.70 0.78 0.77 
Cognitions 28.8 (16.8) 27.0-32.2 0.60 0.79 0.84 
Communication 28.1 (21.0) 25.1-31.5 0.78 0.79 0.74 
Body pain 42.0 (23.5) 38.5-45.9 0.75 0.76 0.75 
PDSI** 35.1 (15.4) 23.1-36.7 0.93 ---- 0.80 
* Activities of daily living 
** Parkinson's disease summary index 
 
Validation of Persian version of PDQ-39 Nojomi et al 
JRMS/ March & April 2010; Vol 15, No 2. 67 
 Discriminate validity of PDQ-39 was as-
sessed by comparing scores of domains and 
PDQ-SI by severity (Table 3) and duration of 
disease (data is not shown). The patients with 
mild, moderate, and severe stages of Parkin-
son's disease had an average summary index 
score of 28 (SD = 14.3), 40 (SD = 12.4) and 46.7 
(SD = 16.4), respectively. There was a statisti-
cally significant difference between scores of 
patients with mild versus moderate and severe 
disease (p = 0.005). The difference in score for 
domain of mobility was also significant be-
tween mild versus moderate and severe dis-
ease (p < 0.05). However, the difference of 
score between mild versus moderate for the 
emotions domain was not significant. No other 
significant differences were found between 
scores of other domains for moderate versus 
severe disease. Differences of scores for mild 
versus moderate and severe stages for these 
domains were significant (p < 0.05). 
 Respondents with disease duration of more 
than five years had lower scores on the PDQ-SI 
and all domains of PDQ-39 as compared to 
those with less than five years disease dura-
tion. 
Discussion 
The present study assessed the validity and 
reliability of the Persian version of the PDQ-39 
in 200 patients with Parkinson's disease. This 
validation was performed in hospital-based
clinics setting. The results from this investiga-
tion provide evidence that the translated ver-
sion of PDQ-39 is a valid and reliable measure 
of quality of life in Parkinson's disease pa-
tients. The internal consistency of question-
naire for the summary score was high (the 
Cronbabach's α coefficient = 0.93). The internal 
consistency of 7 of the 8 scales was satisfactory 
(≥ 0.70). The internal consistency of "cogni-
tions" was less than the level of considered sat-
isfactory (α = 0.60). In the original validation 
study a value of 0.84 was gained for the sum-
mary score.11 The alpha coefficient for "cogni-
tions" in the original questionnaire was 0.74.9
In a number of studies, the coefficient for this 
domain has ranged between 0.71 and 0.82.9,16,17 
Some evidence has cast doubt on the reliability 
of the cognitions and social support domains 
with alpha values of less than 0.70 being re-
ported.16,18,19 
The intraclass correlation coefficient for 
summary score and domains of PDQ-39 
ranged from 0.47 to 0.90 indicating good re-
producibility of questionnaire. All domains but 
one gained ICCs greater than 0.70. The present 
study provided evidence of a strong correla-
tion between scores on all items and their par-
ent domains (0.73-0.84). 
 The PDQ-39 was compared with SF-36 in 
order to assess construct validity. The correla-
tion between PDQ domains and related meas-
ures on the SF-36 ranged from -0.55 to -0.61  
 
Table 3. Mean (SD) PDQ-39 scores by severity of disease (HY) 
 
Domain Mild (n = 86) Moderate (n = 78) Severe (n = 23) P value 
Mobility 31.7 (19.2) 53.1 (20.7) 65.5 (16.4) 0.0005 
ADL* 28.3 (18.9) 46.8 (20.0) 55.9 (22.8) 0.0005 
Emotions 32.2 (19.2) 38.7 (19.8) 53.2 (23.8) 0.0005 
Stigma 28.3 (23.1) 39.3 (24.6) 42.3 (28.2) 0.004 
Social support 18.8 (17.9) 25.2 (19.5) 34.4 (27.7) 0.005 
Cognition 23.1 (14.9) 32.8 (16.3) 37.5 (19.4) 0.005 
Communication 22.4 (19.0) 34.0 (21.0) 34.9 (22.2) 0.005 
Body pain 34.9 (23.1) 47.9 (20.3) 50.0 (28.2) 0.005 
PDSI** 28.0 (14.3) 40.0 (12.4) 46.7 (16.4) 0.005 
* Activities of daily living 
** Parkinson's disease summary index 
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(the correlation is negative due to inverse scor-
ing algorithms). These results are in agreement 
with those previously reported in the litera-
ture.16
In order to determine the discriminate va-
lidity of PDQ-39, the mean PDQ-SI was com-
pared between categories of disease duration 
and HY stages. This study revealed that sever-
ity of disease affects quality of life of patients. 
The patients with mild stage of disease had the 
lower score of PDQ-SI and all domains of 
PDQ-39 as opposed to moderate and severe 
stages. This finding was similar to other stud-
ies.16,20 For 5 of 8 domains, any significant dif-
ference couldn't be found between moderate 
and severe stages of disease. One explanation 
for this may be the similar level of quality of 
life of patients at the end stages of disease. Al-
ternatively, the finding may be due to the 
small sample size of patients in these two 
stages, especially for severe stage. However, 
except for the emotions dimension, the Persian 
version of PDQ-39 did discriminate between 
mild versus moderate and severe stages of dis-
ease. In the study of Souza et al the impact of 
disease on quality of life was higher in the 
lower stages of disease for dimensions of emo-
tional and cognitive aspects.20 They explained 
this finding due to emotional problems of dis-
ease at the first stages of disease. Some studies 
showed that the dimensions of social support 
and stigma are almost constant during the dis-
ease progression.21
The questionnaire also revealed a good dis-
criminate ability according to the duration of 
disease, with patients with longer duration of 
disease having higher scores on the PDQ-SI 
(worse quality of life). This finding has been 
reported elsewhere.20
Conclusions 
In conclusion, present results demonstrate that 
the Persian version of PDQ-39 is useful for as-
sessing quality of life of Parkinson's disease 
patients in a clinical setting. It is a short and 
easily understood instrument that can be self-
administered. The evidence presented here in-
dicates that the PDQ-39 is a valid and reliable 
instrument that can be used in future studies 
of PD in Iran. This study did not assess the re-
sponsiveness of the PDQ-39. Consequently, 
future research should determine minimally 
important differences for domains of the Per-
sian version of the questionnaire. 
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